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BACKGROUND: Elderly individuals react less efficiently to vaccines than do adults, mainly because of T-cell unresponsiveness. In this
study, we analysed whether tumour-associated antigen (TAA)-specific CD8 T-cell responses could be induced by vaccination in old
mice with metastatic breast cancer.
METHODS: The effect of pcDNA-3.1- and Listeria-based vaccines, expressing TAA Mage-b, on Mage-b-specific immune responses was
tested in spleens and draining lymph nodes (LNs) of mild (4TO7cg) and aggressive (4T1) syngeneic metastatic mouse breast tumour
models at young (3 months) and old (20 months) age.
RESULTS: Interferon g and interleukin-2 levels increased significantly in draining LNs and spleens of Mage-b-vaccinated mice compared
with those in control groups at young but not old age in both mouse tumour models. A significant increase was observed in the
number of IFNg-producing Mage-b-specific CD8 T cells after Mage-b vaccination in the 4T1 model at young but not old age. This
correlated with a reduced protective effect of Mage-b vaccination against metastatic breast cancer at old compared with young age.
CONCLUSIONS: The absence of CD8 T-cell responses after Mage-b vaccination and the accompanying reduced protection against
metastatic breast cancer in old compared with young mice point towards the need for tailoring cancer vaccination to older age.
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Elderly women have much higher breast cancer incidence and
mortality rates than do young women. As demographic trends
indicate that over the next few decades the number of elderly
women will increase substantially, strategies for breast cancer
prevention and therapy need to be optimised to older patients.
Current treatment options for localised breast cancer include
surgical resection of primary tumour, assessment of regional
lymph nodes (LNs) and removal, if positive, followed by adjuvant
chemotherapy or hormonal therapy (Scarth et al, 2002). Cancer
vaccines are less toxic than chemotherapy or radiation and could,
therefore, be especially useful for elderly, often frail patients.
However, it has been reported that elderly individuals react less
efficiently to flu and pneumococcal vaccines than do younger
adults, because of T-cell unresponsiveness (McElhaney et al, 1994;
Quyang et al, 2000). Therefore, research is required to establish
whether age-specific tumour immunological variables permit the
optimal use of cancer vaccines for the prevention and therapy of
cancer in the elderly.
Thus far, all cancer vaccines used in clinical trials have only
been tested in preclinical models at young age. However, more
recent data demonstrate that age is an important factor for the
efficacy of cancer vaccines. For instance, Provinciali et al (2003)
showed that immunisation with a pCMVneuNT DNA vaccine was
effective in young but not old mice bearing neu-expressing breast
tumours. This correlated with high levels of anti-neu antibodies
induced by the vaccine in young but not in old mice. Lustgarten
et al (2004) showed that immunisation with a pre-B-lymphoma cell
line (BM-185) expressing GFP and CD80 (B7.1) induced long-
lasting immune responses and tumour rejection of wild-type BM-
185 tumours at young but not old age. However, when co-
administered with anti-OX-40 mAbs, vigorous long-lasting im-
mune responses and tumour rejection were observed at both
young and old age. A similar effect of anti-OX40 was observed in a
syngeneic prostate cancer model at young and old age (Sharma
et al, 2006). A conclusion that can be drawn from these studies is
that none of the vaccines were effective at older age, but that
tailoring the vaccines to older age seems feasible.
In this study, we analysed the effects of vaccination in preclinical
mouse tumour models of metastatic breast cancer at young and old
age. In contrast to primary tumour, metastases cannot be removed
by surgery or radiation, and most metastases are chemoresistant
(Pardal et al, 2003). Thus, metastases and not primary tumours are
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sthe most important contributor to breast cancer morbidity and
mortality. To study the efficacy of cancer vaccination against
breast cancer metastases, two different preclinical metastatic
breast tumour models were used, that is, 4TO7cg, which is a
relatively mild model with 2–20 metastases per mouse, and the
much more aggressive 4T1 with 5–300 metastases per mouse. Both
models highly express Mage-b tumour-associated antigen (TAA)
in their primary tumours and metastases (Gravekamp et al, 2004,
2008). Mouse Mage-b is homologous to human MAGE-B (Lurquin
et al, 1997). MAGE antigens are particularly interesting for the
development of breast cancer vaccines, because their expression
(MAGE-A and MAGE-B) has been frequently detected in human
breast biopsy samples (Park et al, 2002). Clinical trials not only
demonstrate the potential of MAGE-based vaccines against
metastases, but also the need for further improvement (Thurner
et al, 1999; Marchand et al, 2003; Kruit et al, 2005; Van Baren et al,
2005). In this study, we demonstrate that vaccination with Mage-b
induces CD8 T-cell responses at young but not old age, which
correlated with a stronger protective effect on metastases at young
than at old age. These results imply that strategies for cancer
vaccination against breast and possibly other cancers should be
tailored to older age.
MATERIALS AND METHODS
Mice
BALB/c mice aged 3 and 20 months were obtained from the
Harlan/National Institute of Aging Laboratories (Wilmington, MA,
USA) and were maintained in the animal husbandry facility of the
University of Texas Health Science Center San Antonio, according
to the Association and Accreditation of Laboratory Animal Care
guidelines. The mean lifespan of female Balb/C mice is 25.5±4.6
months (Anisimov, 2001).
Plasmids
The mouse Mage-b DNA plasmid (pcDNA3.1-Mage-b/V5) has
been described previously (Sypniewska et al, 2005). The mouse
granulocyte macrophage-colony stimulating factor (GM-CSF)
plasmid (CMV1-GM-CSF) was kindly provided by Dr Stephen
Johnston (The Center for Innovations in Medicine, The Biodesign
Institute at Arizona State University) (Chambers and Johnston,
2003). The Listeria monocytogenes (LM)-based vaccine, expressing
a fragment of Mage-b DNA (position: 311–660) as fusion protein
with ListeriolysinO (LLO), designated as LM-LLO-Mage-b311–660,
has been described previously (Kim et al, 2008). The LM-LLO used
in this study is attenuated, that is, the coding region for the
C-terminal part of the LLO (cytolytic domain that binds
cholesterol in the membranes) protein has been deleted. Mutations
have been introduced into the prfA gene (expressed by the pGG34
vector), which reduced the pathogenicity of LM (Singh et al, 2005).
Cells and cell culture
The metastatic 4T1 cell line was derived from a spontaneous
mammary carcinoma in a BALB/c mouse (Aslakson and Miller,
1992). 4TO7 and 64pT cell lines were derived from a spontaneous
mammary carcinoma in a BALB/cfC3H mouse (Rak et al, 1992). A
sub-line of 4TO7 has been developed in our laboratory (4TO7cg)
and is metastatic as well (Sypniewska et al, 2005). All mouse
mammary tumour cell lines were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 1mM mixed non-essential amino acids, 2mM
L-glutamine, insulin (0.5 HSPUnits per ml), penicillin (100Units
per ml), and streptomycin (100mgml
 1).
Breast tumours and metastases
Breast tumours and metastases were generated in BALB/c mice by
the injection of 10
5 cells of mouse mammary tumour cell line
4TO7cg or 4T1 into a mammary fat pad as described previously
(Sypniewska et al, 2005; Gravekamp et al, 2008). Primary tumours
were detected by palpation within 1–2 weeks in live mice. Twenty-
two days after injection of the tumour cell line, mice were killed,
weighed, and necropsied to evaluate the presence and frequency of
metastases, as well as to determine the weight and size of primary
tumours. 4TO7cg is mildly metastastic with 2–20 metastases per
mouse (Sypniewska et al, 2005). The 4T1 cell line used in this study
is highly aggressive with 5–300 metastases per mouse. Primary
tumours extend to the chest cavity lining and metastasise pre-
dominantly to the mesenteric LNs (MLNs), and less frequently to
the diaphragm, portal liver, and surface of the spleen and kidneys
(Kim et al, 2008). Metastases were visible to the naked eye as
nodules. The total number of metastases per mouse was deter-
mined. Normal and tumour tissues were collected aseptically and
kept at  801C, or fixed in 10% zinc solution for 48h and kept in
70% ethanol, until use.
RT–PCR and Southern blotting
RNA was isolated using Trizol according to the manufacturer’s
instructions (Life Technologies, Carlsbad, CA, USA). Conversion
of 1mg mRNA into cDNA was carried out using the Superscript
Pre-amplification System (Life Technologies). Subsequently, 10ml
of cDNA was amplified by hot start PCR (Platinum PCR SuperMix,
Life Technologies) (40 cycles at 941C for 30s, 501C for 30s, 721C
for 2min) in a thermocycler from Perkin-Elmer (Norwalk, CT,
USA). The primers used for the detection of Mage-b and b-actin
(internal control for RNA quality) have been described previously
(Sypniewska et al, 2005). The RT–PCR products were separated
in an ethidium-bromide-stained agarose gel, transferred to
an Immobilon-N
þ membrane (Amersham, Buckinghamshire,
England), and hybridised with a chemiluminescence-labelled,
sequence-verified 993-bp Mage-specific probe (AY196960) accord-
ing to the manufacturer’s instructions (enhanced chemilumine-
scence; Amersham).
Immunisation and tumour challenge
For both mouse tumour models, that is, 4TO7cg and 4T1, different
immunisation protocols were used. Using the 4TO7cg model, Balb/
C mice were immunised as described previously (Sypniewska et al,
2005) and outlined in Figure 1A. Briefly, mice were immunised
intramuscularly in both quadricepses at days 0 and 21 with 100ml
of pyrogen-free saline containing 50mg of the Mage-b1/2 DNA
vaccine (pcDNA3.1/Mage-b1/2-V5) or the control vector
(pcDNA3.1/V5 or pcDNA3.1-LacZ/V5), or with 100ml saline only.
Two weeks after the last immunisation, mice were injected with 10
5
4TO7cg tumour cells into a mammary fat pad. Four weeks after
tumour challenge, the mice were killed and analysed for the
frequency and location of metastases, and for the size of
the primary tumours. Using the 4T1 model, Balb/C mice were
immunised as described previously (Gravekamp et al, 2008) and
outlined in Figure 1B. Briefly, mice were injected with 1ml of 2.9%
(w/v) TGB (Brewer thioglycollate broth B2551, Sigma-Aldrich, St
Louis, MO, USA) into the peritoneal cavity to recruit professional
antigen-presenting cells (APCs), that is, macrophages, to the
peritoneal cavity (Yasuda et al, 2004). Four days later, they were
immunised intraperitoneally with 100mg of Mage-b (pcDNA3.1-
Mage-b) or with 100mg of the control vector (pcDNA3.1), or saline.
To improve the processing and presentation of the vaccine antigen,
the vaccine and control vectors were mixed with 100mgo f
a plasmid-secreting GM-CSF. Granulocyte macrophage-colony
stimulating factor plasmid DNA of 100mg was also added to the
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ssaline group. Three and six weeks later, an identical second
immunisation was performed. For tumour induction, mice were
injected with 10
5 4T1 tumour cells into a mammary fat pad 2 weeks
after the second immunisation. Primary tumours were palpable
about 8–10 days after tumour cell injection. Twenty-two days after
tumour challenge, the mice were killed and analysed for tumour
size, frequency, and location of metastases.
To determine the efficacy of the LM-LLO-Mage-b311–660 vaccine,
Balb/C mice were immunised intraperitoneally (thrice; 1-week
time interval) with 0.1 LD50 (10
7CFU) of the vaccine, 0.1 LD50
of the control vector (LM-LLO), or with saline as described
previously (Kim et al, 2008) and outlined in Figure 1C. For tumour
induction, mice were injected with 10
5 4T1 tumour cells into a
mammary fat pad 4 days after the second immunisation. Fourteen
days after tumour challenge, the mice were killed and analysed for
tumour size, frequency and location of metastases.
Re-stimulation of the spleen and LN cells in vitro
Re-stimulation of cells from the spleen or draining LNs of mice
that were vaccinated with pcDNA3.1-Mage-b was performed as
described previously (Sypniewska et al, 2005). Briefly, spleen cells
(5 10
6ml per well) of vaccinated and control mice were re-
stimulated by transient transfection with 0.5mg of Mage-b DNA
using Lipofectamine plus (Invitrogen, Carlsbad, CA, USA) in 24
cluster-well plates. Cells from draining LNs of vaccinated and
control mice were re-stimulated with g-irradiated (40Gy) 64pT
tumour cells (0.5 10
6 LN cells per ml and 2 10
5 or 5 10
4 64pT
tumour cells per ml). All re-stimulation assays were performed in
DMEM, containing 10% FBS. For determining interleukin (IL)-2
and interferon (IFN)g levels, supernatants were tested by
quantitative enzyme-linked immunosorbent assay (ELISA) 24
and 72h after re-stimulation, respectively. Quantitative ELISA
was performed according to the manufacturer’s instructions
(Pharmingen, San Diego, CA, USA).
Re-stimulation of spleen cells of mice that were vaccinated with
LM-LLO-Mage-b311–660 was performed as described previously
(Kim et al, 2008). Briefly, 2 10
5 spleen cells were re-stimulated in
microtitre wells with 5 10
4 autologous bone marrow (BM) cells
(transfected with pcDNA3.1-Mage-b plasmid DNA and pCMV-
GM-CSF plasmid DNA; 1mg of each plasmid DNA per 5 10
6 BM
cells), using the Nucleofector kit of AMAXA (Gaithersburg, MD,
USA). Two days later, the frequency of IFNg-producing cells was
determined by ELISPOT for both re-stimulation assays according
to standard protocols (Pharmingen), using an ELISPOT reader
(CTL Immunospot S4 Analyzer, Cellular Technology Ltd, Cleve-
land, OH, USA). Spleen cells were depleted for CD8 T cells using
magnetic bead depletion techniques according to the manufac-
turer’s instructions (Miltenyi Biotec Inc, Auburn, CA, USA).
Fluorescence-activated cell sorter (FACS) analysis demonstrated
that X90% of all CD8 T cells were depleted.
FACS analysis of spleen cells
Spleen cells of young and old Mage-b-vaccinated and control mice
bearing 4T1 tumours (15–20 mice per group) were pooled and
analysed for the production of intracellular IFNg, without in vitro
re-stimulation. CD8 and CD4 T cells were analysed, as well as
macrophages (anti-Mac3), natural killer (NK) cells (anti-CD49b),
and B cells (anti-CD19). Analyses were carried out with non-gated
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Figure 1 Schematic depiction of immunisations in 4TO7cg and 4T1 mice. (A) 4TO7cg mice were twice immunised intramuscularly (im) with pcDNA3.
1-Mage-b, pCDNA3.1, or with saline at days 1 and 21. Two weeks after the last immunisation, mice were injected with 10
5 4TO7cg tumour cells into a
mammary fat pad. Four weeks later, mice were killed and analysed. (B) 4T1 mice were immunised intraperitoneally (ip) with pcDNA3.1-Mage-bþGM-CSF,
pCDNA3.1þGM-CSF, or salineþGM-CSF at days 1, 21, and 42. All mice of the 4T1 model received thioglycollate broth (TGB) ip 4 days before each
immunisation (grey short arrow). At day 39, mice were injected with 10
5 4T1 tumour cells into a mammary fat pad. Four weeks later, they were killed and
analysed. (C) BALB/c mice were immunised thrice intraperitoneally with 0.1 LD50 (10
7CFU) of Listeria-based Mage-b311–660 vaccine, 0.1 LD50 of
LM-LLO vector control, or with saline, using 1-week time intervals. Four days after the second immunisation, mice were injected with 10
5 4T1 tumour cells
in a mammary fat pad. Two weeks after tumour challenge, mice were killed and analysed. Young mice were 3 months of age, and old mice 20 months.
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scell populations (10000 cells per sample), and isotype-matched
controls (CD8 (IgG2a), CD4 (IgG2b), Mac3 (IgG1), CD49b (IgG),
and CD19 (IgG2a)) were used in each sample. Samples were
analysed by the Flow Cytometry Core of the Cancer Therapy and
Research Center (San Antonio, TX, USA) using a FACS (Calibur,
BD Biosciences, San Jose, CA, USA). All antibodies were purchased
from Pharmingen.
RESULTS
Expression of Mage-b in metastases and tumours at old age
In a previous study, we showed that Mage-b is highly expressed
in 4TO7cg metastases and tumours in young and old mice
(Gravekamp et al, 2004). We have also shown that Mage-b is
highly expressed in 4T1 metastases and tumours of young mice
(Gravekamp et al, 2008). To confirm that Mage-b is also expressed
in the 4T1 metastases and primary tumours of old mice (n¼5
mice), we randomly analysed tissues of 4T1 metastases (MLN,
diaphragm, liver, spleen, and kidneys), primary tumours, and
several normal tissues by RT–PCR and Southern blotting. As
expected, all primary tumours and metastases expressed Mage-b,
except one metastasis present on the surface of the spleen, which
may have lost Mage-b expression as b-actin was highly expressed
(Figure 2). In none of the normal tissues could Mage-b transcripts
be detected.
Effect of vaccination on 4TO7cg and 4T1 metastases and
primary tumours at young and old age
Before the vaccine studies, we first analysed whether ageing had an
effect on the growth of metastases and primary tumours in the two
syngeneic metastatic mouse breast tumour models, 4TO7cg and
4T1. Some effect of ageing was observed in the 4TO7cg model, but
this was not significant. Although primary tumours were some-
what smaller in old than in young mice, the number of metastases
was somewhat higher in old than in young mice (saline groups of
Figure 3A–D). We cannot exclude the possibility that the
somewhat higher number of 4TO7cg metastases at old compared
with young age is due to age-related spontaneous tumours in the
lungs and peritoneal cavity. These spontaneous tumours also
express Mage-b (unpublished results). Age-related effects on the
growth of 4TO7cg tumours and metastases have also been
extensively analysed in a previous study (Gravekamp et al, 2004).
In contrast to 4TO7cg, a dramatic effect of ageing was observed
in the 4T1 model. The number of metastases (Mann–Whitney
P¼0.0492) was significantly lower and tumour growth
(Mann–Whitney Po0.0001) was less aggressive and significantly
lower in old than in young mice of the 4T1 model (saline groups of
Figure 3E–H). Slower progression of tumours in old hosts has also
been observed in other animal models, such as a B16 melanoma
model (Ershler, 1984), an EMT6 lung tumour model (Rockwell,
1981), and in an AKR lymphoma model (Itzthaki et al, 2000).
Vaccination of Mage-b (pcDNA3.1-Mage-b) was first tested in
the less-aggressive 4TO7cg model (number of metastases varies
between 2–20) at young and old age. At young age, a significant
effect of vaccination on metastases was observed in the Mage-b
group compared with both control groups (Figure 3A), whereas at
old age, the effect was less robust and no significant differences
were observed between vaccinated and control groups (Figure 3B).
The effect of Mage-b vaccination on primary tumours was not
significant at both ages (Figure 3C and D).
After testing Mage-b DNA in the relatively mild metastatic
breast tumour model 4TO7cg, we repeated the vaccine study in the
highly aggressive 4T1 model. However, in this aggressive model
(number of metastases varies between 5–300), the vaccine had
initially little effect on metastases (unpublished results). Therefore,
we improved the vaccination protocol by adding plasmid DNA-
secreting GM-CSF to the Mage-b DNA vaccine, aiming to improve
the activation of APCs, such as macrophages. In addition, we
recruited APCs more efficiently into the peritoneal cavity by the
injection of thioglycollate broth (TGB) before each vaccination,
aiming to improve subsequent DNA uptake. At young age, a
significant effect of vaccination with Mage-b and GM-CSF on
metastases was observed (Figure 3E). A similar protective effect
was observed at old age, although it was considerably less robust
(Figure 3F). We also determined the sizes of primary 4T1 tumours
after dissecting them from killed mice. At both ages, the average
weight of primary tumours was significantly lower in vaccinated
mice compared with the control groups (Figure 3G and H).
Next, to further improve DNA uptake in vivo and the
subsequent in vivo efficacy of Mage-b vaccination, we used an
attenuated LM-based vaccine, expressing a Mage-b fragment
(nucleotide position: 311–660) as a fusion protein with LLO
(Kim et al, 2008). Listeria monocytogenes delivers the vaccine
antigen with very high efficiency into APC, such as monocytes and
macrophages (Paterson and Maciag, 2005). Using this vaccine, a
dramatic effect was observed on metastases at young age
(Figure 3I), with a less robust but still significant effect at old
age (Figure 3J). However, Mage-b vaccination did not reduce the
growth of 4T1 primary tumours at both ages (Figure 3K and L).
Mage-b-specific immune responses in vitro at young and
old age in the 4TO7cg and 4T1 model
To determine whether Mage-b-specific immune responses corre-
lated with vaccine efficacy (effect of vaccine on metastases
and tumours), we analysed pcDNA3.1-Mage-b-induced immune
responses in the spleen and draining LNs of tumour-bearing mice
at young and old age. Cells were re-stimulated with Mage-b DNA
or with syngeneic 64pT tumour cells, highly expressing Mage-b.
At young age, a strong increase in the levels of IL-2 and IFNg was
observed in the vaccine group, compared with the control groups
of the 4TO7cg model (Figure 4A and B). However, at old age, the
levels of IL-2 and IFNg were almost undetectable (Figure 4A and B).
Similar results were obtained with the 4T1 model but Mage-b-
specific immune responses were weaker in the 4T1 than in the
4TO7cg model at young age (Figure 4C and D). Although IL-2 and
IFNg levels were significantly higher in the Mage-b than in the
control groups for both models (at young age), the control groups
showed immune responses to Mage-b as well. This may be because
the spleens and LNs of all groups were isolated from mice with
tumours and metastases, highly expressing Mage-b.
We also analysed Mage-b-specific immune responses in the
spleens of young and old mice vaccinated with LM-LLO-Mage-
b311–660. In this experiment, spleen cells of LM-LLO-Mage-b311–660-
vaccinated or control mice were re-stimulated with BM cells
transfected with pcDNA3.1-Mage-b and pCMV1-GM-CSF.
Although strong CD8 responses to Mage-b were observed at
Mage-b
-Actin
1 2       3       4 5       6       7      8     9    10     11 12     13   14
Figure 2 Expression levels of Mage-b in metastases and primary
tumours of the 4T1 model at old age. The Mage-b-specific RT–PCR
products of 632bp were detected by Southern blotting using a DNA
probe encoding Mage-b. b-actin was used as RNA control for each sample.
The lanes were loaded as follows: lanes 1 and 2, 4T1 primary tumours;
lanes 3 and 4, metastases mesenteric lymph nodes (LNs); lanes 5 and 6,
metastases liver; lanes 7 and 8, metastases spleen; lanes 9 and 10,
metastases liver; lanes11 and 12, metastases diaphragm; and lanes 13 and
14, normal breast. Tumour and normal tissues were randomly analysed
from different mice (n¼5). Two representative examples of each tissue
are shown in this figure.
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syoung age, as shown by the reduction in the number of IFNg-
producing cells (IL-2 is not produced) after the depletion of CD8 T
cells, at old age CD8 T-cell responses were completely absent
(Figure 4E). In summary, the results of these studies demonstrate
that Mage-b-specific CD8 T-cell responses can be induced by
vaccination with Mage-b DNA at young but not old age.
Mage-b-specific immune responses in vivo at young and
old age in the 4T1 model
To analyse Mage-b-specific immune responses at young and old
age in more detail in the 4T1 model, CD8 T cells, CD4 T cells,
macrophages, NK cells, and B cells in the spleens of Mage-b-
vaccinated and control mice were analysed for the production of
intracellular IFNg (Figure 5). To analyse Mage-b-specific immune
responses directly in vivo, spleen cells were analysed without in
vitro re-stimulation. At young age, an increase in the percentage of
IFNg-producing CD8 T cells was observed in Mage-b-vaccinated
mice compared with both control groups, whereas at old age,
IFNg-producing CD8 T cells were almost undetectable. The
percentage of IFNg-producing CD4 T cells was low or undetectable
in vaccinated or control mice at young age, but decreased in the
control vector and in Mage-b-vaccinated mice compared with the
saline control group at old age. The percentage of IFNg-producing
macrophages and NK cells increased moderately in Mage-b-
vaccinated compared with control mice at old age and was not
detectable at young age. The percentage of IFNg-producing B cells
decreased in Mage-b-vaccinated compared with control mice at
young age, but was low and did not alter at old age.
DISCUSSION
Elderly individuals react less efficiently to vaccines than do adults,
mainly because of T-cell unresponsiveness. In this study, we
analysed whether cancer vaccination was more effective in young
than in old mice with metastatic breast cancer. Various parameters
were compared, such as (1) the growth of metastases and primary
tumours in mice without vaccination to determine the age-related
effect on cancer, (2) in vivo efficacy of Mage-b vaccination, and (3)
CD8 T-cell responses induced by vaccination with Mage-b DNA. A
mild (4TO7cg) and a highly aggressive (4T1) metastatic mouse
tumour models were used. Overall, the effect of vaccination on the
growth of metastases and tumours was more robust at young than
at old age. However, differences in vaccine efficacy were found
between the two models. In the mild 4TO7cg model, a significant
effect of vaccination with pcDNA3.1-Mage-b on metastases was
only observed at young age, whereas in the highly aggressive 4T1
model, a strong effect was found on metastases and primary
tumours at both ages, although the effect was more robust at
young than at old age.
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Figure 3 The effect of Mage-b vaccination on metastases and primary tumours at young and old age in 4TO7cg and 4T1 models. The effect of vaccination
with pcDNA3.1-Mage-b was measured on the growth of metastases and primary tumours of the 4TO7cg model (A–D). Young (3 months) and old (20
months) mice were immunised and challenged with 4TO7cg tumour cells as described in Figure 1A. The number of metastases per mouse was determined
in young (panel A) and old (panel B) mice. Furthermore, tumour weight was determined in young (panel C) and old (panel D) mice. At young age n¼15
mice per group, and at old age n¼7 mice per group. Results were averaged per group and subjected to statistical analysis using the Mann–Whitney test
(Po0.05 is significant). This experiment was performed once. The effect of Mage-b vaccination was also measured on the growth of metastases and primary
tumours of the 4T1 model (E–H). Young and old mice were immunised and challenged with 4T1 tumour cells as described in Figure 1B. The number of
metastases per mouse was determined in young (panel E) and old (panel F) mice. Furthermore, tumour weight was determined in young (panel G) and old
(panel H) mice. The results shown in this study are the average of three independent experiments, and subjected to statistical analysis (Mann–Whitney
Po0.05 is significant). n¼5–10 mice per group. Each triangle represents one mouse. In addition, the effect of vaccination with LM-LLO-Mage-b311–660 was
measured on the growth of metastases and primary tumours of the 4T1 model at young and old (I–L) age. Young and old mice were immunised and
challenged with 4T1 tumour cells as described in Figure 1C. The number of metastases per mouse was determined in young (panel I) and old (panel J) mice.
Moreover, tumour weight was determined in young (panel K) and old (panel L) mice. Results were averaged per group and subjected to statistical analysis
(Mann–Whitney Po0.05 is significant). In this experiment, n¼5 mice per group, and the experiment was performed once. In all figures, the results in the
Mage-b group were compared with those in both control groups; error bars represent s.e.m.
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sVarious factors may contribute to the difference in vaccine
efficacy between the two models. For instance, in the 4T1 model,
but not in the 4TO7cg model, GM-CSF and TGB were added to the
pcDNA3.1-Mage-b vaccine. Both agents highly activate macro-
phages (Yasuda et al, 2004; Shi et al, 2006), which may have
contributed to the reduction in tumour growth at young and old
age. Tumour-associated macrophages (TAMs) present within the
tumour have a crucial role in the suppression and activation of the
immune system in cancer patients. Macrophages may secrete
factors or lymphokines such as IL-6, TGFb, IL-10, or prostaglan-
dine E (PGE)2, which inhibit T-cell responses, or macrophages may
secrete IFNg or IL-12, which activates T-cell responses (for a
review, see Gravekamp et al, 2009). However, TAM can also
become tumouricidal when producing IFNg and TNFa (Baron-
Bodo et al, 2005; Ouyang et al, 2006), or promote angiogenesis by
secreting IL-8, migration inhibitory factor, or vascular endothelial
growth factor (Shih et al, 2006). Therefore, control of TAM is an
important consideration for cancer immunotherapy.
Granulocyte macrophage-colony stimulating factor and TGB
may not be the only factors involved in the stronger effect of
vaccination with Mage-b in the 4T1 model compared with the
4TO7cg model. Furthermore, ageing, especially in the 4T1 model,
had an important role in the growth of metastases and primary
tumours. A dramatic decrease in the growth of metastases and
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Figure 3 Continued.
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sprimary tumours of the saline group at old compared with young
age was observed in the highly metastatic 4T1 model, but was less
pronounced and not significant in the mildly metastatic 4TO7cg
model. This could not be because of GM-CSF and TGB, as the
dramatic age-related effect on the growth of metastases and
primary tumours was also observed in the vaccine study with LM-
LLO-Mage-b311–660, in which GM-CSF and TGB were not included.
If the in vivo efficacy of Mage-b vaccination is less robust in old
than in young mice, is this because of decreased Mage-b-specific
immune responses at old age? Three different methods were used
to analyse Mage-b-specific immune responses in the spleens and
LNs, namely quantitative ELISA, ELISPOT, and FACS. Only at
young age could CD8 T cells be activated with Mage-b in the 4T1
model, and only at young age did IL-2 and IFNg increase
significantly in the spleens and LNs of Mage-b-vaccinated
compared with control mice in the 4TO7cg model. Hence, this
shows that vaccination with Mage-b DNA activates CD8 T cells at
young but not at old age, which correlated with a significant effect
on metastases at both ages, although the effect was less robust at
old than at young age. The unresponsiveness of CD8 T cells to
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Figure 4 Mage-b-induced immune responses (in vitro) at young and old age in the 4TO7cg and 4T1 model. Mage-b-induced immune responses were
determined at young and old age. Mice were vaccinated (pcDNA3.1-Mage-b) and challenged with 4TO7cg or 4T1 tumour cells, as shown in Figure 1A or B,
respectively. Cells from spleens were transfected with Mage-b DNA, and draining LNs were re-stimulated with syngeneic 64pT breast tumour cells, highly
expressing Mage-b. The production of IL-2 by cells in the spleen (A and C) and of IFNg by cells in the draining lymph nodes (LNs) (B and D) of vaccinated
and control mice was determined by quantitative ELISA. Controls such as nonstimulated cells from spleens or draining LNs were negative (data not shown).
All experiments were performed in triplicate and subjected to statistical analysis using the Tukey–Kramer Multiple Comparison test (Po0.05 is significant).
The cytokine levels produced in the Mage-b group were compared with those produced in the saline and vector control groups. At young age n¼10 mice
per group, and at old age n¼15. Mice were also vaccinated with LM-LLO-Mage-b311–660 and challenged with 4T1 tumour cells, as shown in Figure 1C. Cells
from spleens were re-stimulated with bone marrow cells transfected with pcDNA3.1-Mage-b and pCMV1-GM-CSF plasmid DNA. Two days later, Mage-b-
specific immune responses were analysed by ELISPOT (E). Involvement of Mage-b-specific CD8 T cells was determined by negative depletion, using
magnetic beads with anti-CD8 antibodies. Controls such as BM cells transfected with pcDNA3.1-Mage-b or with pCMV-GM-CSF, and nontransfected BM
cells were negative (data not shown). All experiments were performed in triplicate. n¼5 mice per group, and were used once. Results were averaged and
subjected to statistical analysis using the Mann–Whitney test (Po0.05 is significant). The number of IFNg-producing cells in the Mage group was compared
with that in the saline and vector control groups. In all figures, cells from spleens or draining LNs were pooled; error bars represent the s.e.m.
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of naive T cells, or poorly functioning CD4 T cells at older
age (George and Ritter, 1996; Grubeck-Loebenstein, 1997; Haynes
et al, 2003).
Which immune cells or factors contributed to fewer metastases
at older age is not clear yet. In preliminary studies with pcDNA3.
1-Mage-b, we analysed macrophages and NK cells, as well as
apoptotic pathways in metastases. We found that fewer metastases
at old age correlated with lower expression levels of active caspase-
3 and a decrease in the expression levels of Fas, FasL, and TRAIL
(data not shown). Although these results suggest that immune cells
(perhaps macrophages) rather than tumour cells are responsible
for the observed lower expression levels of active caspase-3,
analysis of tumour-infiltrating immune cells and tumour cells,
separately, will be necessary to determine the contribution of each
cell type to the expression level of active caspase-3 in metastases at
old age.
Weak-to-moderate responses of macrophages and NK cells were
observed in Mage-b-vaccinated compared with control mice at
old age (Figure 5). These innate immune responses may have been
studied too late after vaccination (4 weeks after the last
vaccination) and could have been more robust at earlier time
points. More research will be necessary to determine the role of
macrophages and NK cells in cancer vaccination at older age.
From studies with LM-LLO-Mage-b311–660, a possibility emerged
that could provide an alternative explanation for the significant
effect of vaccination on metastases in the absence of Mage-b-
specific CD8 T-cell responses at old age. As recently discovered,
Listeria bacteria infect and kill tumour cells without the need of
Mage-b-specific CD8 T cells, resulting in the complete eradication
of metastases and an almost complete eradication of primary
tumours at young age (Kim et al, 2009). Therefore, in this study,
the effect of LM-LLO-Mage-b311–660 vaccination on metastases
at old age (Figure 4E) may have been because of the Listeria-
induced kill.
Thus far, all cancer vaccines in clinical trials are based
on preclinical studies at young age. The results of this study
and studies reported by others (Provinciali et al, 2003; Lustgarten
et al, 2004; Sharma et al, 2006) demonstrate the importance of
the age factor in cancer vaccination. However, these results also
suggest that cancer vaccination is feasible at older age
and that further improvement and tailoring to older age in
preclinical animal models before human application is of crucial
importance.
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